Wang W, Macapinlac H, Larson S M, Yeh S D, Akhurst T, Finn R D, Rosai J, Robbins R J
Department of Radiology, The Laurent and Alberta Gerschel Positron Emission Tomography Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
J Clin Endocrinol Metab. 1999 Jul;84(7):2291-302. doi: 10.1210/jcem.84.7.5827.
Progressive dedifferentiation of thyroid cancer cells leads to a loss of iodine-concentrating ability, with resultant false negative, whole body radioactive iodine scans in approximately 20% of all differentiated metastatic thyroid cancer lesions. We tested the hypothesis that all metastatic thyroid cancer lesions that did not concentrate iodine, but did produce thyroglobulin (Tg), could be localized by [18F]2-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET). We performed FDG-PET on 37 patients with differentiated thyroid cancer after surgery and radioiodine ablation who had negative diagnostic 131I whole body scans during routine follow-up. Serum Tg, Tg autoantibodies, neck ultrasounds, and other clinically indicated imaging procedures were performed to detect residual disease. In those with elevated Tg levels, FDG-PET localized occult disease in 71%, was false positive in one, and was false negative in five patients. The majority of false negative FDG-PET occurred in patients with minimal cervical adenopathy. Surgical resections, biopsies, 131 therapy, and differentiation therapy were performed based on the PET results. The FDG-PET result changed the clinical management in 19 of the 37 patients. In patients with elevated Tg levels, FDG-PET had a positive predictive value of 92%. In patients with low Tg levels, FDG-PET had a negative predictive value of 93%. No FDG-PET scans were positive in stage I patients; however, they were always positive in stage IV patients with elevated Tg levels. An elevated TSH level (i.e. hypothyroidism) did not increase the ability to detect lesions. FDG-PET is able to localize residual thyroid cancer lesions in patients who have negative diagnostic 131I whole body scans and elevated Tg levels, although it was not sensitive enough to detect minimal residual disease in cervical nodes.
甲状腺癌细胞的渐进性去分化导致碘摄取能力丧失,约20%的分化型转移性甲状腺癌病灶会出现全身放射性碘扫描假阴性结果。我们检验了这样一个假设:所有不摄取碘但能产生甲状腺球蛋白(Tg)的转移性甲状腺癌病灶,都可以通过[18F]2-氟-2-脱氧-D-葡萄糖(FDG)-正电子发射断层扫描(PET)进行定位。我们对37例分化型甲状腺癌患者进行了手术及放射性碘消融治疗,在常规随访期间其诊断性131I全身扫描结果为阴性,对这些患者进行了FDG-PET检查。检测血清Tg、Tg自身抗体、颈部超声以及其他临床指示的成像检查以发现残留病灶。在Tg水平升高的患者中,FDG-PET定位隐匿性病灶的成功率为71%,1例假阳性,5例假阴性。大多数FDG-PET假阴性发生在颈部淋巴结病变轻微的患者中。根据PET结果进行了手术切除、活检、131治疗及分化治疗。37例患者中有19例的临床管理因FDG-PET结果而改变。在Tg水平升高的患者中,FDG-PET的阳性预测值为92%。在Tg水平较低的患者中,FDG-PET的阴性预测值为93%。I期患者的FDG-PET扫描均为阴性;然而,Tg水平升高的IV期患者的FDG-PET扫描总是阳性。促甲状腺激素(TSH)水平升高(即甲状腺功能减退)并未提高检测病灶的能力。FDG-PET能够对诊断性131I全身扫描阴性且Tg水平升高的患者中的残留甲状腺癌病灶进行定位,尽管其对检测颈部淋巴结微小残留病灶的敏感性不足。